Bispecific antibody · Immune activation, directed at PD-1 (PDCD1) and TIM-3 (HAVCR2) · developed by ASTRAZENECA
AZD7789 (sabestomig) is a bispecific antibody that binds both PD-1 and TIM-3, two inhibitory immune checkpoint receptors co-expressed on tumor-antigen-specific T cells. By blocking these receptors' interactions with their ligands, it aims to relieve T-cell inhibition and enhance T-cell-mediated tumor cell killing. It is being studied in advanced or metastatic non-small cell lung cancer.
Summary written with AI from the sources listed at the end of this page.
Advanced or Metastatic NSCLC
Updated Nov 1, 2026. Something wrong or missing? Report it on the AZN page.
See AZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
AZN catalysts and pipeline →